Replies to post #3393 on Antares Pharma, Inc. (ATRS)

[jab91252]

What I find interesting is the Courts note about ATRS v Medac dosing:

"As to the public interest, Antares avers that its product is available and in use for the same indications as Medac's product, i.e., rheumatoid arthritis and psoriasis. Medac responds that the products are not interchangeable as RASUVO provides additional dosing flexibility not offered through OTREXUP. AS OVER 90% OF PRESCRIBED DOSES ARE FOR THE STANDARD DOSES THAT ANTARES ALREADY SELLS, THIS FACTOR IS NEUTRAL." (I put the last sentence in all caps for the emphasis and to draw attention to this Court statement)

So, OTREXUP addresses the already 90% standard dosing of mtx available today, does RASUVO's potential market niche only cover the remaining 10%??